Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

How scientists discovered CoolSculpting fat-freezing technology


Many years ago, scientists at Harvard University noticed that some children who ate pop ices got dimples in their cheeks. This led Dieter Manstein, MD and R. Rox Anderson, MD, to realise that ice can selectively damage small pockets of fat cells.

Eventually this idea that cold can target fat cells— without damaging the skin or surrounding tissue— was the discovery behind cryolipolysis, the science on which the CoolSculpting (fat-freezing) procedure is based.

CoolSculpting (fat-freezing) is a non-surgical fat reduction treatment which kill the fat cells to 25% Over the next 5-8 weeks the dead cells are naturally metabolised and digested by your body as if they were a waste product.

Procedure Safety

CoolSculpting technology delivers controlled cooling to target the fat cells underneath the layer of skin, whilst leaving no damage to the skin. There are no needles, and there is minimal downtime after treatment. To date CoolSculpting has been performed over 7 million treatment cycles.

Clinician Safety

CoolSculpting specialists at Pulse Light Clinic have undergone in-depth training, and CoolSculpting provide ongoing support to Pulse Light Clinic to help ensure high standards of care.

Device Safety

The CoolSculpting systems are controlled cooling devices designed with built-in safety measures. If sensors detect that the skin is getting too cold, the system will shut down automatically.

Pulse Light Clinic London have specialised in laser and skin treatments for over 18 years. Treatments ranging from laser hair removal, laser tattoo removal, non-surgical body sculpting with EmSculpt and CoolSculpt and skin treatments to help with Rosacea, Pigmentation, Acne Scars and more.

Share article on social media or email:

Active Immunotherapeutic PD01A for Parkinson’s Disease Phase I Clinical Study


MDS Virtual Congress 2020

We still do not have a treatment for PD to stop or slow the disease progression, and this is one of the first tested immunizations against alpha-synuclein in PD patients.

Results from a clinical study of the active immunotherapeutic PD01A for Parkinson’s Disease provide basis for a phase II study, according to a study released today at the MDS Virtual Congress 2020.

Although there are many therapeutic treatments for Parkinson’s disease (PD), there remains no approved way to stop disease progression. Aggregation of the alpha-synuclein (aSyn) protein is hypothesized to be an underlying cause of PD. Recent developments in immunotherapies that intervene in the aSyn aggregation provide hope of a disease modifying treatment.

PD01A, an aSyn active immunotherapeutic for patients with PD, underwent a phase I study for long-term safety and immunogenicity. Participants with early PD received immunizations at differing concentrations (randomized) and were re-randomized before receiving a booster. Total time in the study ranged from 228 weeks to 297 weeks. Treatment emergent adverse events (TEAEs), motor status, antibody titers, and cerebral spinal fluid (CSF) antibody concentrations were recorded. Although some participants experienced a transient skin reaction, no patient discontinued the study due to TEAEs. Motor symptoms were stable throughout the four years of the study, and the oligomeric aSyn of interest in the CSF was reduced.

Brit Mollenhauer, Attending Physician at Movement Disorder Paracelsus-Elena-Klinik and Assistant Professor at University Medical Center Goettingen in Kassel, Germany states, “We still do not have a treatment for PD to stop or slow the disease progression, and this is one of the first tested immunizations against alpha-synuclein in PD patients. This approach is an active immunization with a short antigenic peptide formulation in a small set of patients, that is not given in the abstract, but from the press release from 2014 is n=12 from a single center. The sample and data analysis has taken a long time, but the decrease in oligomeric aSyn in cerebrospinal fluid with a correlation and improvement of motor symptoms in the higher dose regimen is very promising. No clinical trial has yet reported a substantial improvement in motor symptoms, but even a stabilization as reported here would be important. Nevertheless, this is a small cohort and needs further validation. Other companies are currently carrying out passive immunizations in larger, multi-center phase 2 trials, and the field is very eager for positive results to stop the disease.”

About the MDS Virtual Congress 2020: Meeting participants will learn the latest research findings and state-of-the-art treatment options in Movement Disorders, including Parkinson’s disease. Over 14,000 physicians and medical professionals from more than 130 countries will participate virtually to view over 30 hours of educational content and 1,500 scientific abstracts submitted by clinicians from around the world.

About the International Parkinson and Movement Disorder Society: The International Parkinson and Movement Disorder Society (MDS), an international society of over 8,500 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

Multicenter, Deep Brain Stimulation Study Suggests Increased Range of Effective Stimulus Amplitude Using Directional vs. Omnidirectional Leads


MDS Virtual Congress 2020

DBS should be personalized and it is likely that as technology evolves, we will take a more individualized approach to each patient and each symptom.

A study released today at the MDS Virtual Congress 2020 examines the therapeutic window of stimulus amplitude between directional and omnidirectional leads used in deep brain stimulation.

Deep brain stimulation (DBS) is a therapeutic treatment for Parkinson’s disease. DBS can provide relief of symptoms including bradykinesia, rigidity, tremor, and loss of balance. Leads are implanted in the brain—specifically, the subthalamic nucleus in the study presented here — and connected to a programmable pulse generator. The range of amplitudes that can achieve symptom relief without causing additional side effects is termed the therapeutic window (TW).

Here, a double-blind, randomized comparison study examined the therapeutic window (TW) for both directional and the omnidirectional DBS leads. Participants received omnidirectional stimulation for three months and directional stimulation for three months. During each trial period both the TW of the device and the motor symptoms were assessed. Over 90% of participants experienced an increased TW, averaging near 40%, with the directional leads relative to the omnidirectional leads.

Participants and clinicians also were able to rate their preference for each period of the study. Interestingly, 53% of participants preferred the directional lead period, whereas 59% of clinicians preferred this period. Of participants, 26% preferred the omnidirectional period and 21% had no preference.

Micheal Okun, MD, Medical Director at the Parkinson’s Foundation and Professor and Chair, University of Florida, offers his comment on the study, stating “This study and studies like this will be required to better understand if the use of segmented deep brain stimulation leads in order to ‘steer the current’ will ultimately improve the benefit to side effect ratio for an individual patient. The data suggests that there exists a subset of patients where using this methodology yields a better therapeutic window though the overall outcomes were similar in both groups (segmented leads vs. omnidirectional). DBS should be personalized and it is likely that as technology evolves, we will take a more individualized approach to each patient and each symptom.”

About the MDS Virtual Congress 2020: Meeting participants will learn the latest research findings and state-of-the-art treatment options in Movement Disorders, including Parkinson’s disease. Over 14,000 physicians and medical professionals from more than 130 countries will participate virtually to view over 30 hours of educational content and 1,500 scientific abstracts submitted by clinicians from around the world.

About the International Parkinson and Movement Disorder Society: The International Parkinson and Movement Disorder Society (MDS), an international society of over 8,500 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

Early Inflammation as a Potential Predictor of Severe Decline in Nigrostriatal Function


MDS Virtual Congress 2020

The primary message is that there is clear inflammation in the earliest stages of PD, which identifies those who will progress faster in the future.

Participants who exhibited baseline markers of neuroinflammation in the substantia nigra showed the most severe decline in nigrostriatal function over the course of the study, according to research released today at the MDS Virtual Congress 2020.

Isolated REM sleep behavior disorder (iRBD) can lead to neurodegeneration and parkinsonism. However, the role of the microglia in the progression of neurodegeneration in these patients remains unknown.

In this study, K. Staer and colleagues utilized PET tracers to mark the activation of the microglia and progression of nigrostriatal dysfunction in patients with iRBD. The group has reported in previous studies that this PET tracer for activation of microglia can be used to monitor neuroinflammation in the substantia nigra even in the absence of clinical evidence for parkinsonism. Researchers observed a significant decrease in the nigrostriatal function in participants over the three-year study period. Participants with an elevated baseline microglial activation exhibited the most severe declines in nigrostriatal function.

Ron Postuma, MD, MSc, Department of Neurology Professor at McGill University, commented on the study, stating, “This study covers a very interesting area. The primary message is that there is clear inflammation in the earliest stages of PD, which identifies those who will progress faster in the future. Of course, even from a prospective study one cannot establish any sort of causal relationship – inflammation could cause faster degeneration (which is certainly plausible), or it may be that those patients with more inflammation were already having more severe degeneration, which gradually became evident as further decline on dopaminergic imaging.”

About the MDS Virtual Congress 2020: Meeting participants will learn the latest research findings and state-of-the-art treatment options in Movement Disorders, including Parkinson’s disease. Over 14,000 physicians and medical professionals from more than 130 countries will participate virtually to view over 30 hours of educational content and 1,500 scientific abstracts submitted by clinicians from around the world.

About the International Parkinson and Movement Disorder Society: The International Parkinson and Movement Disorder Society (MDS), an international society of over 8,500 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

The Association of Loneliness with Quality of Life and Disease Severity in Parkinson’s Disease


MDS Virtual Congress 2020

“loneliness can be seen to be associated with higher severity of PD regardless of age”

According to a study released today at the MDS Virtual Congress 2020, loneliness in Parkinson’s disease (PD) patients was associated with increase disease severity.

Although PD is considered a disease of the motor system, and thus is a movement disorder, the importance of non-motor aspects is becoming increasingly apparent. Understanding the role and impact of things such as loneliness and social isolation on disease severity can help clinicians provide the best guidance and care possible.

In this study, the PROMIS Global scale was used to assess quality of life and the PRO-PD to assess the disease severity in patients diagnosed with idiopathic PD. Using a cross-sectional analysis, the authors found that participants who reported feeling lonely had higher disease severity scores. Whereas, lower disease severity scores were associated with regular exercise and having many friends. The authors conclude with emphasizing the importance of the role of the clinician in encouraging social interaction and connection with others.

Janis Miyasaki, MD, MEd, FRCPC, Professor at the University of Alberta, commented on the study, stating, “This is an interesting study of a large cohort of individuals completing the PROMIS quality of life instrument and a PD severity self-completed scale. This demonstrated an association between loneliness and worse severity of PD. This is interesting as it aligns with recent work on loneliness and worsened outcomes for the elderly – to the extent that the UK government is funding social events to mitigate this effect. This study is also interesting that age did not account for rating oneself higher for loneliness and thus, loneliness can be seen to be associated with higher severity of PD regardless of age.”

Miyaski continues, “The weakness of this study is that other aspects of the history are not included: actual diaries or self-report of activities outside of the home, the presence of a caregiver in the home, whether individuals were on congregant living for seniors or those with health conditions. Depression and anxiety were not included in the regression model and thus, patient report may be affected by the presence of mood disorders.”

“Nonetheless, this speaks to the importance of socialization for our patients and the challenge of apathy to engage our patients in activities that can improve their quality of life.”

About the MDS Virtual Congress 2020: Meeting participants will learn the latest research findings and state-of-the-art treatment options in Movement Disorders, including Parkinson’s disease. Over 14,000 physicians and medical professionals from more than 130 countries will participate virtually to view over 30 hours of educational content and 1,500 scientific abstracts submitted by clinicians from around the world.

About the International Parkinson and Movement Disorder Society: The International Parkinson and Movement Disorder Society (MDS), an international society of over 8,500 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

CBD Validator’s Latest Industry Report Finds Large Price Disparities and No Relationship Between Premium Pricing and Quality Manufacturing Across CBD Products


“Our mission is to create transparency for consumers,” notes Dr. Robert Portman, CEO of CBD Validator. “Our initial report discovered wide price gaps among similar CBD products, and now it seems that even more products are continuing this pricing inconsistency.”

CBD Validator, an independent industry resource that owns the largest database of rated CBD oil products on the market today, shares its latest report, Large Pricing Variation Between Equivalent CBD Products Fuels Consumer Confusion. This report analyzes more than 2,000 CBD oils, a 39% increase in product coverage from the first retail pricing report published earlier this year, with both reports concluding the continued wide price differences among similar CBD products, creating more consumer mistrust and confusion within this rapidly growing industry.

“Our mission is to create transparency for consumers, and the research and data we have focuses on one of the most significant factors that impacts the CBD industry,” notes Dr. Robert Portman, CEO of CBD Validator. “Our initial report discovered huge price gaps among similar products, and now with this second report, it seems that even more products are continuing the inconsistency.”

The CBD industry has been rapidly evolving, and given the unfortunate widespread impact of the COVID pandemic, there have been significant economic and lifestyle changes everywhere, as people seek alternative ways to cope and adapt to this “new normal.” According to a report from the Brightfield Group, “… the US CBD market is projected to reach $4.7 billion in sales, with 14% growth from 2019 sales of $4.1 billion. With Americans facing high unemployment levels (11.1 % in June compared to 3.8% in February of this year), 2020’s retail sales are not expected to reach levels anticipated prior due to the emergence of the COVID-19 pandemic.” But, despite key challenges including “…economic pressures faced by consumers, temporary store closures, inaction by the US FDA (Food and Drug Administration) constraining growth of the US CBD market, it estimates the total US CBD market still could reach $16.8 billion by 2025.”

CBD Validator’s pricing research and data continues to find great disparities across equivalent CBD products, specifically in the CBD oils and tinctures category:

KEY DATA POINTS

  • The average cost per milligram of CBD across all products in the CBD Validator database is $0.18, a 2% decline from the average reported seven months prior (Feb 2020), which most likely reflects a drop in the price of hemp due to oversupply.
  • The seven most popular strengths of CBD oils and tinctures are 250 mg, 300 mg, 500 mg, 600 mg, 750 mg, 1000 mg and 1500 mg.
  • The 500 mg and 1000 mg strengths of CBD sold in a one-ounce bottle account for almost 30% of all products reported in the CBD Validator database.
  • An example of pricing disparity is illustrated in analyzing the 1000 mg strength. The average MSRP for the 1000 mg strength is $93.20, but the range is quite significant — $30 for the least expensive and $214.99 for the most expensive, or a seven-fold difference. In fact, across all strengths there is on average, a six-fold difference between the most and least expensive product.

KEY INSIGHTS

Pricing disparities create consumer confusion and will continue to serve as an obstacle to the growth and mainstream use of CBD. More importantly, there appears to be no relationship between premium pricing and quality manufacturing. Only 19% of the 1000 mg strength CBD oils in the CBD Validator database provide consumers with a Certificate of Analysis (CoA) for CBD (a document issued by an independent testing laboratory to assure a product meets specification), pesticides and heavy metals from an independent testing laboratory.

About CBD Advanced Science and CBD Validator

CBD Advanced Science was established to provide consumers with a much-needed resource to help make informed decisions when purchasing CBD products. The company is committed to providing consumers with unbiased information about the growing number of CBD products marketed today, with its CBD Validator digital tool. CBD Validator is the first comprehensive and easy-to-use digital tool that allows consumers to evaluate and compare 2000+ CBD oils and tinctures. Each product receives a CBD Validator Score based on how it meets the key criteria outlined in the proprietary 50-point rating system. As an aggregator of product information, CBD Validator does not assess the validity of claims made by a manufacturer.

CBD Validator is a completely independent resource, not sponsored by any manufacturer of CBD products, and does not accept advertising or receive sales commissions from any manufacturers or marketers of CBD products.

For more information, please visit CBD Validator or follow us on LinkedIn, Instagram, Facebook and Twitter.

Share article on social media or email:



AspenRidge Recovery Opens New Location in Colorado Springs


I’m thrilled our new location will bring quality, evidence-based treatment to both the civilian and veteran populations in El Paso County.

AspenRidge Recovery, a leading Colorado drug and alcohol rehabilitation center, today announced it opened a fourth location in Colorado Springs. The new facility brings much-needed treatment options to the residents of El Paso County during National Recovery Month.

The new location lead by Kellyanne Achramowicz, MS, NCC, LPC, ADS, serves as a hub for AspenRidge Recovery’s Intensive Outpatient Program and comes less than three months after the company opened a third location in Lone Tree.

“Colorado Springs is a treatment desert at this level of care,” said Achramowicz. “Our city lacks options for adults who need treatment for substance abuse and co-occurring mental disorders. I’m a military brat and treated veterans for years, so I’m thrilled our new location will bring quality, evidence-based treatment to both the civilian and veteran populations in El Paso County.”    

The new Colorado Springs office expands the company’s portfolio of treatment centers. AspenRidge Recovery currently operates three centers in Lakewood, Lone Tree and Fort Collins that feature day programs, recovery residences, IOP and outpatient programs. The company continues to grow and recently opened a second men’s house in Fort Collins and launched an online IOP option called REACH, which allows anyone in Colorado, Florida and Michigan to access treatment from the comfort of their homes.

“Finding addiction and mental health treatment during a global pandemic is especially challenging,” said Ethan Castro, CEO of AspenRidge Recovery. “Look at any news site, and you’ll see countless stories of skyrocketing overdose rates across America. We hope that our new Colorado Springs location will increase access, help minimize the amount of overdoses and bring high-quality treatment available to anyone ready to ask for help.”

AspenRidge Recovery Colorado Springs is enrolling new clients with groups forming immediately. AspenRidge accepts most major insurance policies and offers affordable options for those without health insurance. The new location is located at 2860 South Circle Drive, Suite G30A, Colorado Springs, CO 80906. For more information, call (719) 220-8730.

About AspenRidge Recovery

AspenRidge Recovery is a Joint Commission-accredited, dual-diagnosis treatment center specializing in treating co-occurring substance use disorders, mental health disorders and complex trauma for adults. AspenRidge provides personalized, unique treatment plans addressing specific needs by using a combination of holistic and evidence-based mental health, trauma, and addiction treatment modalities. AspenRidge Recovery has physical locations in Lakewood, Fort Collins, Lone Tree and Colorado Springs, Colorado. For more information, visit https://www.aspenridgerecoverycenters.com.

Share article on social media or email:

Makers Nutrition Swoops Twelve Stevie® Awards in the 2020 International Business Awards®


Makers Nutrition Swoops Twelve Stevie® Awards in the 2020 International Business Awards®

People depend on us to provide their customers with safe and high-quality supplements, and we are proud to follow through for all of their health and wellness needs.

MAKERS NUTRITION was named the winner of twelve Stevie® Awards in the 17th Annual International Business Awards®.

The International Business Awards are the world’s premier business awards program. All individuals and organizations worldwide – public and private, for-profit and non-profit, large and small – are eligible to submit nominations. The 2020 IBAs received entries from organizations in 63 nations and territories.

As the ongoing COVID-19 crisis will prevent winners from receiving their awards on stage during a traditional gala IBA banquet, winners will be celebrated instead during a virtual ceremony on Tuesday, 1 December.

More than 3,800 nominations from organizations of all sizes and in virtually every industry were submitted this year for consideration in a wide range of categories, including Company of the Year, Marketing Campaign of the Year, Best New Product or Service of the Year, Startup of the Year, Corporate Social Responsibility Program of the Year, and Executive of the Year, among others. This year’s competition also featured a number of free-to-enter categories to recognize organizations’ and individuals’ response to the COVID-19 pandemic.

Makers Nutrition garnered the following titles in the 2020 IBAs:

1. GOLD – Company of the Year in Consumer Products – Durable

2. GOLD – Company of the Year in Pharmaceuticals

3. GOLD – Fastest-Growing Company of the Year in Canada and the U.S.A.

4. GOLD – Executive of the Year – Executive Vice President Stephen Finnegan in Health Products & Services

5. SILVER – Company of the Year in Business or Professional Services

6. SILVER – Company of the Year in Consumer Services

7. BRONZE – Company of the Year in Health Products & Services

8. BRONZE – Company of the Year in Manufacturing

9. BRONZE – Executive of the Year – COO Christopher Zecha in Manufacturing

10. BRONZE – Management Team of the Year

11. BRONZE – Most Valuable Service During COVID-19

12. BRONZE – Most Valuable Product During COVID-19 Crisis

This is Makers Nutrition’s third year participating in the International Business Awards®. “While each year is a testament to how committed our team is to both the company’s success and that of its clients, we are exceptionally honored to serve as an essential business throughout the COVID-19 crisis,” said Executive Vice President Stephen Finnegan. “People depend on us to provide their customers with safe and high-quality supplements, and we are proud to follow through for all of their health and wellness needs.”

Stevie Award winners were determined by the average scores of more than 250 executives worldwide who participated in the judging process from July through early September.

“Despite the unprecedented impact the COVID-19 pandemic has had on organizations and working people worldwide, the number and quality of nominations we received in this year’s International Business Awards attests to the continued outstanding performance of many organizations. The commitment we’ve seen through these nominations to maintaining the success, health, and safety of employees, customers, and communities is truly impressive,” said Stevie Awards president Maggie Gallagher.

Details about The International Business Awards and the lists of Stevie Award winners are available at http://www.StevieAwards.com/IBA.

About Makers Nutrition

Makers Nutrition, an Inc. 5000 Fastest-Growing Company in America, is a groundbreaking provider for dietary supplement companies worldwide. Specializing in capsules, tablets, powders, softgels and gummies, Makers Nutrition provides a full-service option for all contract manufacturing, graphic design, packaging, and fulfillment service needs. Click here to learn more.

About the Stevie Awards

Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Share article on social media or email:

Navigating the Current Landscape for Successful Dermatology Trials, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

The speakers will share insights on how Synteract has been able to realign and adapt quickly and with minimal disruption – offering case studies and site status updates, including how the company was able to achieve eight database locks in the last four months.

Although many trials hit “pause” when the pandemic disrupted everyday life, the clinical research industry pivoted quickly and definitively, moving as many trials as possible back on track, while streamlining the process and maintaining (or even improving) patient and data integrity. At Synteract, we were able to transition swiftly and keep studies progressing, getting creative with troubleshooting options and closing studies without significant impact in timelines.

If your dermatology trial encountered challenges since the pandemic struck – or if you are wondering how to resume or start new trials – join this live webinar on Tuesday, September 22, 2020 at 11am EDT (4pm BST/UK) presented by Synteract Dermatology team experts Betsey Zbyszynski, the senior director of strategic development in dermatology, Nancy Fitzgerald, the biostatistics director and Craig Dorer-Abadia, the director of dermatology project management.

Together, they will address the current dermatology landscape, the impact of COVID-19 on trials and the “new norm” and examine how some sponsors are responding. The speakers will share insights on how Synteract has been able to realign and adapt quickly and with minimal disruption – offering case studies and site status updates, including how the company was able to achieve eight database locks in the last four months.

For more information or to register for this event, visit Navigating the Current Landscape for Successful Dermatology Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Crystal Structure Determination in Solid Form Drug Development, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

Growing a sufficiently large, good quality, single crystal can sometimes still be a challenge and a bottleneck, even when crystals smaller than 100-μm can now routinely be used.

Join this live webinar on Tuesday, September 22, 2020 at 1pm EDT (10am PDT), presented by Dr. Steef Boerrigter, Senior Research Scientist, AMRI.

Single crystal structure solution using X-ray diffraction analysis (SC-XRD) plays an important role in drug development. SC-XRD fully elucidates the molecular structure and can be used to confirm successful chemical synthesis of the molecule. Many drug molecules are chiral. In addition to being the most reliable, SC-XRD is the only generally applicable method to determine the absolute configuration, i.e. the three-dimensional structure of the molecular bonds.

Growing a sufficiently large, good quality, single crystal can sometimes still be a challenge and a bottleneck, even when crystals smaller than 100-μm can now routinely be used. Several growing techniques will be discussed in this upcoming webinar.

Given high resolution powder X-ray diffraction (PXRD) data, most often the unit cell parameters and space group can be determined by finding an indexing solution to the observed peak positions, also known as indexing. The resulting unit cell volume can be used to identify the contents and stoichiometry, and the index of a PXRD pattern reveals if extraneous Bragg peaks exist, indicating form impurities.

In patents, solid forms are usually claimed by lists of characteristic peaks in the PXRD. Collecting PXRD data is often straightforward, though pitfalls exist.

Join this webinar to learn more!

For more information or to register for this event, visit Crystal Structure Determination in Solid Form Drug Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email: